Late-Breaking Data at EADV Shows Investigational Drug Litifilimab For Cutaneous Lupus Show Durable Symptom Control
The Lupus Research Alliance is encouraged by positive 52-week Phase 2 data (ongoing Phase 2/3 AMETHYST Study) with litifilimab, an investigational drug in...
